Results 151 to 160 of about 13,497 (214)

Efficacy and safety of CT-868, a novel, fully biased, dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double-blind, randomized placebo controlled phase 2 trial. [PDF]

open access: yesDiabetes Obes Metab
Chakravarthy MV   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy